Slide 1: Schedule 14A Consent Statement - Puma Biotechnology, Inc.
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a–101) INFORMATION REQUIRED IN CONSENT STATEMENT SCHEDULE 14A INFORMATION Consent Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ¨ Filed by a Party other t
Slide 2: Slide 2
Slide 3: Selected slides from Puma's presentation with Dr. Eshelman's commentary
Destroying Selected slides from Puma Biotechnology Inc.’s presentation, dated December 4, 2015. This presentation represents Dr. Fredric N. Eshelman’s commentary on Puma’s arguments.
Slide 4: Debunking Puma's Claim To Be Developing Stockholder Value
Debunking Puma’s Claim To Be Developing Stockholder Value ManagementandBoardunableto unlockstockholdervalue: Pumahasa valuableassetthat couldgenerate significant value for stockholders if managed correctly. To date, Puma’s current Board and management team have failed to do so. Lackof strategicplan:
Slide 5: There are only 3.5 weeks left in 4Q '15
There are only 3.5 weeks left in Still haven’t 4Q ’15 –yet disclosed no definite which data Stated on 11/13/14 would file in 1H’15. (two days dates, places before ). or journals (other than On 8/10/15 anticipated publishing in Q3‘15. On SABCS) have 5/11/15 and 3/2/15 anticipated publishing mid- been
Slide 6: Company identifies 10 peers to show other companies have 5 directors
However, on slide 11 the Company manages to identify 10 peers in order to show that 2 other life sciences companies also have 5 directors. The Company provides no discernible basis or source for its list of peers. The Company has consistently claimed that it is The Company does not identify a peer g
Slide 7: Independent directors own very little stock
NOT No independent director has purchased shares within the last two years. The overwhelming majority of shares Puma’s 4 independent beneficially owned directors own very little by the stock: independent • Combined 3.22% directors are beneficial ownership options granted as • Combined 0.003% of part
Slide 8: Puma's statements on Dr. Eshelman's litigation and metrics
Puma’s The Company This is a false and gave no misleading such accusation. Dr. Eshelman assurances expressly offered . that potentially The Company material only responded information be as required by redacted and Delaware law stated that he when Dr. was not seeking We made no such assumption and E
Slide 9: Our nominees would add significantly to the board
Our nominees would add significantly to the Dr. Eshelman board: has extensive • Over a century experience in of combined early stage industry cancer experience companies. • Key roles in over $10 billion in M&Asales. • Central roles in Dr. Rudnick developing or developed launching two different numer
Slide 10: Comparison of PPDI and Cougar under the current board's standards
By the standards the current board uses to judge its own past, PPDI The Company compares very neglects that favorably. PPDI sold most of these at an increase of analyst 421% over its initial statements listing price, while came during a Cougar’s value only two-year increased by 140%, period when and
Slide 11: If the current board really has an overall strategic business plan
If the current board really has an overall strategic business plan, beyond hoping for an eventual acquisition, it has never described it. The current board should outline its own strategic plan for investors and provide evidence that the necessary groundwork is being done. The Nominees have The Comp
Slide 12: Certain Disclosures
Certain Disclosures DR. FREDRIC N. ESHELMAN (“DR. ESHELMAN”) DOES NOT ASSUME RESPONSIBILITY FOR INVESTMENT DECISIONS. THIS PRESENTATION DOES NOT RECOMMEND THE PURCHASE OR SALE OF ANY SECURITY. UNDER NO CIRCUMSTANCES IS THIS PRESENTATION TO BE USED OR CONSIDERED AS AN OFFER TO SELL OR A SOLICITATION